{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:44:16Z","timestamp":1792619056865,"version":"4.5.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Advanced pelvic squamous cell carcinoma (pSCC) is a broad category of cancers affecting different pelvic organs and usually featuring unfavorable clinical outcomes. Thus, we aimed to assess genomic differences among pSCC cases and learn whether pSCC could potentially benefit from targeted therapies and\/or immunotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>A total of 1917 advanced pSCCs, including penile (penSCC), male urethral (murthSCC), male anal (manSCC), female urethral (furthSCC), vulvar (vulSCC), cervical (crvSCC), female anal (fanSCC), and vaginal (vagSCC), underwent comprehensive genomic profiling (CGP). We used hybrid capture-based CGP to evaluate recurrent genomic alterations (GAs). Tumor mutational burden (TMB) was determined on up to 1.1 Mb of sequenced DNA and microsatellite instability (MSI) was determined on up to 95 loci. Programmed cell-death-ligand-1 (PD-L1) expression was determined by immunohistochemistry (IHC; Dako 22C3).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>PIK3CA was the most frequently identified potentially \u201cactionable\u201d GA (22%-43%), followed by mTOR pathway [PTEN (0%-18%), FBXW7 (7%-29%)], and cell-cycle GAs. DNA-damage response (DDR) GAs and receptor-tyrosine kinase (RTK) targeted options were uncommon. NOTCH1 GAs were present in &amp;gt;15% of penSCC and vulvSCC. TMB\u2005\u226510 mut\/Mb was\u2005&amp;gt;15% in manSCC, fanSCC, crvSCC, and vagSCC. PD-L1 high expression was\u2005&amp;gt;18% in all pSCC except urthSCC, manSCC, and vagSCC. HPV-16\/18 detection was highest in manSCC, fanSCC, and crvSCC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Despite similar histology, pSCCs can differ in GAs and HPV status. Overall, PIK3CA is the most frequent potentially \u201ctargetable\u201d GA followed by mTOR and cell cycle pathway. RTK and DDR GAs are rare in pSCC. Immunotherapy could be considered for pSCC management based on TMB and PD-L1 expression.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac144","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T14:19:26Z","timestamp":1658845166000},"page":"1016-1024","source":"Crossref","is-referenced-by-count":15,"title":["Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-2756","authenticated-orcid":false,"given":"Andrea","family":"Necchi","sequence":"first","affiliation":[{"name":"IRCCS San Raffaele Hospital and Scientific Institute , Milan , Italy"},{"name":"Vita-Salute San Raffaele University , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-1972","authenticated-orcid":false,"given":"Philippe E","family":"Spiess","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center and Research Institute , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bandini","sequence":"additional","affiliation":[{"name":"IRCCS San Raffaele Hospital and Scientific Institute , Milan , Italy"},{"name":"Vita-Salute San Raffaele University , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Basile","sequence":"additional","affiliation":[{"name":"IRCCS San Raffaele Hospital and Scientific Institute , Milan , Italy"},{"name":"Vita-Salute San Raffaele University , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[{"name":"University of Washington, Fred Hutchinson Cancer Center , Seattle, WA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennady","family":"Bratslavsky","sequence":"additional","affiliation":[{"name":"SUNY Upstate Medical University , Syracuse, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jacob","sequence":"additional","affiliation":[{"name":"SUNY Upstate Medical University , Syracuse, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Danziger","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc. , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Lin","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc. , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brennan","family":"Decker","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc. , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan S","family":"Sokol","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc. , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S P","family":"Huang","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc. , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay B","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Kulkarni Reconstructive Urology Center , Pune, Maharashtra , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Ross","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc. , Cambridge, MA , USA"},{"name":"SUNY Upstate Medical University , Syracuse, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"2022120904451415200_CIT0001","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"2022120904451415200_CIT0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2022120904451415200_CIT0003","doi-asserted-by":"crossref","first-page":"11133","DOI":"10.18632\/oncotarget.2563","article-title":"The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal","volume":"5","author":"Eng","year":"2014","journal-title":"Oncotarget"},{"key":"2022120904451415200_CIT0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2016.07.007","article-title":"Risk factors and treatment for recurrent vulvar squamous cell carcinoma","volume":"106","author":"Nooij","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"2022120904451415200_CIT0005","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.euf.2019.07.001","article-title":"Current disease management of primary urethral carcinoma","volume":"5","author":"Janisch","year":"2019","journal-title":"Eur Urol Focus"},{"key":"2022120904451415200_CIT0006","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eururo.2014.10.017","article-title":"EAU guidelines on penile cancer: 2014 update","volume":"67","author":"Hakenberg","year":"2015","journal-title":"Eur Urol"},{"key":"2022120904451415200_CIT0007","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"De Martel","year":"2017","journal-title":"Int J Cancer"},{"key":"2022120904451415200_CIT0008","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"2022120904451415200_CIT0009","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"2022120904451415200_CIT0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"key":"2022120904451415200_CIT0011","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"2022120904451415200_CIT0012","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for pesistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"2022120904451415200_CIT0013","doi-asserted-by":"crossref","first-page":"64","DOI":"10.6004\/jnccn.2019.0001","article-title":"Cervical cancer, version 3.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Koh","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2022120904451415200_CIT0014","doi-asserted-by":"crossref","first-page":"92","DOI":"10.6004\/jnccn.2017.0008","article-title":"Vulvar cancer, version 1.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Koh","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"2022120904451415200_CIT0015","doi-asserted-by":"crossref","first-page":"852","DOI":"10.6004\/jnccn.2018.0060","article-title":"Anal carcinoma, version 2.2018, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Benson","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"2022120904451415200_CIT0016","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"2","key":"2022120904451415200_CIT0017","doi-asserted-by":"crossref","first-page":"e1005965","DOI":"10.1371\/journal.pcbi.1005965","article-title":"A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal","volume":"14","author":"Sun","year":"2018","journal-title":"PLoS Comput Biol"},{"issue":"Database issue","key":"2022120904451415200_CIT0018","doi-asserted-by":"crossref","first-page":"D805","DOI":"10.1093\/nar\/gku1075","article-title":"COSMIC: exploring the world\u2019s knowledge of somatic mutations in human cancer.","volume":"43","author":"Forbes","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2022120904451415200_CIT0019","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jmoldx.2019.06.011","article-title":"A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples","volume":"21","author":"Trabucco","year":"2019","journal-title":"J Mol Diagn"},{"key":"2022120904451415200_CIT0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"2022120904451415200_CIT0021","first-page":"JCO2102767","article-title":"Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion.","author":"Chakravarty","year":"2022","journal-title":"J Clin Oncol"},{"key":"2022120904451415200_CIT0022","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"key":"2022120904451415200_CIT0023","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small molecules, big impact: 20 years of targeted therapy in oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"Lancet"},{"key":"2022120904451415200_CIT0024","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41585-020-00379-4","article-title":"Targetable gene fusions and aberrations in genitourinary oncology","volume":"17","author":"Pederzoli","year":"2020","journal-title":"Nat Rev Urol"},{"key":"2022120904451415200_CIT0025","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1158\/1078-0432.CCR-17-3103","article-title":"Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced cancers of the gastrointestinal tract or anus","volume":"24","author":"Schrock","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2022120904451415200_CIT0026","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.juro.2018.09.056","article-title":"Comparative genomic profiling of refractory and metastatic penile and nonpenile cutaneous squamous cell carcinoma: implications for selection of systemic therapy","volume":"201","author":"Jacob","year":"2019","journal-title":"J Urol"},{"key":"2022120904451415200_CIT0027","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.2014.59.0018","article-title":"Inhibition of the PI3K\/AKT\/mTOR pathway in solid tumors","volume":"34","author":"Lo Russo","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022120904451415200_CIT0028","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jnci\/djz224","article-title":"PIK3CA mutation in HPV-associated OPSCC patients receiving deintensified chemoradiation","volume":"112","author":"Beaty","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"2022120904451415200_CIT0029","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(17)30450-3","article-title":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"18","author":"Kim","year":"2017","journal-title":"Lancet Oncol"},{"key":"2022120904451415200_CIT0030","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","volume":"32","author":"Andr\u00e9","year":"2021","journal-title":"Ann Oncol"},{"key":"2022120904451415200_CIT0031","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.semcancer.2019.07.009","article-title":"PI3K\/Akt\/mTOR inhibitors in cancer: at the bench and bedside","volume":"59","author":"Alzahrani","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"2022120904451415200_CIT0032","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1158\/2159-8290.CD-18-1175","article-title":"Challenges for the clinical development of PI3K inhibitors: strategies to improve their impact in solid tumors","volume":"9","author":"Hanker","year":"2019","journal-title":"Cancer Discov"},{"key":"2022120904451415200_CIT0033","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev.pathol.4.110807.092311","article-title":"PTEN and the PI3-kinase pathway in cancer","volume":"4","author":"Chalhoub","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"2022120904451415200_CIT0034","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12943-018-0857-2","article-title":"FBXW7: a critical tumor suppressor of human cancers","volume":"17","author":"Yeh","year":"2018","journal-title":"Mol Cancer"},{"key":"2022120904451415200_CIT0035","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.1162981","article-title":"FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression","volume":"321","author":"Mao","year":"2008","journal-title":"Science"},{"key":"2022120904451415200_CIT0036","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1158\/1535-7163.MCT-14-0330","article-title":"Suppression of feedback loops mediated by PI3K\/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance","volume":"13","author":"Rozengurt","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"2022120904451415200_CIT0037","doi-asserted-by":"crossref","first-page":"7629","DOI":"10.18632\/oncotarget.5367","article-title":"Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: a systematic review and meta-analysis","volume":"7","author":"Bao","year":"2016","journal-title":"Oncotarget"},{"key":"2022120904451415200_CIT0038","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"2022120904451415200_CIT0039","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/2326-6066.CIR-16-0143","article-title":"Targeted next generation sequencing identifies markers of response to PD-1 blockade","volume":"4","author":"Johnson","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2022120904451415200_CIT0040","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor mutational burden as a predictor of immunotherapy response: is more always better?","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2022120904451415200_CIT0041","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.annonc.2020.07.002","article-title":"The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) \u226510: a decision centered on empowering patients and their physicians","volume":"31","author":"Subbiah","year":"2020","journal-title":"Ann Oncol"},{"key":"2022120904451415200_CIT0042","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia","volume":"306","author":"Weng","year":"2004","journal-title":"Science"},{"key":"2022120904451415200_CIT0043","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/15384101.2017.1395534","article-title":"Notch1 regulates tongue cancer cells proliferation, apoptosis and invasion","volume":"17","author":"Gan","year":"2018","journal-title":"Cell Cycle"},{"key":"2022120904451415200_CIT0044","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1038\/s41467-020-16936-9","article-title":"NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation","volume":"11","author":"Miao","year":"2020","journal-title":"Nat Commun"},{"key":"2022120904451415200_CIT0045","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1124\/molpharm.120.000006","article-title":"Notch1 in cancer therapy: possible clinical implications and challenges","volume":"98","author":"Gharaibeh","year":"2020","journal-title":"Mol Pharmacol"},{"key":"2022120904451415200_CIT0046","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"key":"2022120904451415200_CIT0047","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"key":"2022120904451415200_CIT0048","first-page":"840","article-title":"Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies Cancer","author":"McGregor","year":"2021"},{"key":"2022120904451415200_CIT0049","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1200\/JCO.20.01652","article-title":"Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors","volume":"38","author":"Apolo","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/12\/1016\/47751653\/oyac144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/12\/1016\/47751653\/oyac144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T04:45:54Z","timestamp":1670561154000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/12\/1016\/6650150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":49,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,7,26]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac144","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,7,26]]}}}